Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION363 · 1 trial · 1 indication
Functional impairment to be measured by joint rank analysis of the combined assessment of: In-clinic Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score, time of rescue or discontinuation from Part 1 and entering Part 2 due to a deterioration in function, and ventilation assistance-free survival (VAFS). ALSFRS-R measures functional disease severity. The scale measures four functional domains, bulbar function, gross motor skills, fine motor skills, and respiratory function. The assessment will contain 12 questions scored from 0 (no function) to 4 (full function), with a total possible score of 48, which will indicate the highest level of function. ALSFRS-R will be a part of the combined assessment of joint rank analysis to assess efficacy in Part 1.
| Arm | Type | Description |
|---|---|---|
| ION363 | EXPERIMENTAL | ION363 will be administered by lumbar intrathecal (IT) bolus injection every 12 weeks, with an additional loading dose at 4 weeks, over a 60-week double-blind treatment period in Part 1; every 12 weeks for 84 weeks in the open-label extension treatment period (Part 2), with an additional loading dose administered 4 weeks after the first dose. Patients may continue to receive open-label ION363 every 12 weeks in Part 3 for up to 3 additional years or until ION363 becomes commercially available in the patient's country or until the Sponsor discontinues the development program, whichever occurs earlier. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered by lumbar IT bolus injection every12 weeks, with an additional loading dose at 4 weeks, over a 60-week double-blind treatment period (Part 1). |
| Name | Type | Description |
|---|---|---|
| ION363 | DRUG | ION363 will be administered by IT bolus injection. |
| Placebo | DRUG | Placebo will be administered by IT bolus injection. |
Inclusion Criteria for Part 1: 1. Participants must be ≥10 years of age at the time of informed consent and have signs or symptoms consistent with an ALS disease (in the opinion of the Investigator). 2. Genetic mutation in FUS confirmed by a testing laboratory that is Clinical Laboratory Improvemen...
ION363 is an investigational small molecule being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS). It is specifically studied in patients with Fused in Sarcoma (FUS) mutations, a genetic form of the disease. The drug is currently in Phase 3 clinical development.
ION363 targets FUS, which stands for Fused in Sarcoma. It is designed to address ALS caused by mutations in the FUS gene. The drug is being evaluated in patients with these specific genetic mutations to potentially treat this form of the disease.
ION363 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company. Ionis is listed on the NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with FUS-ALS.
ION363 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to evaluate its efficacy, safety, pharmacokinetics, and pharmacodynamics in patients with FUS-ALS.
ION363 is being studied in a Phase 3 clinical trial with the identifier NCT04768972. This trial, known as FUSION, is evaluating the drug in Amyotrophic Lateral Sclerosis participants with Fused in Sarcoma mutations. The study is active but not recruiting participants and has an enrollment of 89 patients.
No, ION363 is the drug being studied, while FUSION is the name of the clinical trial evaluating it. The trial is formally titled 'FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS).'